Global Overactive Bladder Treatment Market published by Market Research Future which gives a broad study of the different market segments and regions By Pharmacotherapy, by Non-Pharmacological Treatment, by Disease Forecast Till 2023
The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6248
Overactive Bladder (OAB) is a symptom syndrome characterized by urinary urgency. Numerous factors such as the growing prevalence of Overactive Bladder (OAB) coupled with the rising geriatric population, increasing occurrences of Parkinson’s disease, and multiple sclerosis and stroke are likely to drive the growth of the market during the forecast period. For instance, according to the data stated by the Official Foundation of the American Urological Association, in 2016, approximately 33 million Americans had an overactive bladder. It also mentioned that around 30% of men and 40% of women in the US have the symptoms of overactive bladder. Moreover, the development of innovative intravesical therapies and increasing marketing activities by pharma companies contribute to the growth of the market.
Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.
- Astellas Pharma Inc.
- Pfizer, Inc.
- Teva Pharmaceutical
- Allergan, Plc.
- Mylan N.V.
- Endo International Plc
- Hisamitsu Pharmaceutical Co., Inc.
- Sanofi S. A.
- Aurobindo Pharma Limited
- Johnson & Johnson
- Intas Pharmaceuticals Ltd.
- Apotex Inc.
- Macleods Pharmaceuticals Ltd.
- Medtronic PLC
- Cogentix Medical, Inc.
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.
Browse Premium Research Report with Tables and Figures @ https://www.marketresearchfuture.com/reports/overactive-bladder-treatment-market-6248
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312